Press releases

HEUSSEN advises US company Microbiologics on acquisition of Rostock-based biotech pioneer SensID

Stuttgart, 22 November 2024 – The US biotechnology company Microbiologics, Inc., a world leader in quality control for infectious disease diagnostics, has acquired SensID GmbH, a manufacturer of reference materials and quality controls for molecular diagnostics with a focus on oncology and precision medicine, based in Rostock.

The corporate law firm HEUSSEN provided comprehensive legal advice to the acquiring company Microbiologics on the transaction. Particular challenges were the large circle of sellers, including founders and investors, as well as the consideration of new regulations in foreign trade law, which allow the Federal Ministry for Economic Affairs and Climate Protection to apply extended investment controls across all sectors for up to five years after the conclusion of the contract.

With the acquisition of SensID, Microbiologics aims to expand its expertise beyond infectious diseases into the fields of oncology and precision medicine. Together, Microbiologics and SensID will offer improved diagnostic solutions and a broader portfolio of quality control solutions.

SensID was founded in 2015. After the acquisition by Microbiologics, the company will remain based in Rostock and continue to operate as Microbiologics' first location outside the USA.

The HEUSSEN team advising Microbiologics was led by partner Sven Hoffmann (corporate/M&A) and comprised Sarah Ehret (corporate/M&A, foreign trade law), Judith Sommer (labor law), Mark Münch (IT/data protection) and Dr. Sabine Hohmann (IP).

HEUSSEN was brought into the international transaction mandate through the global law firm network MULTILAW and advised together with the US law firm Lathrop GPM.